Hip fracture risk in statin users--a population-based Danish case-control study

Area of Science:

• Pharmacology and Gerontology
• Bone Metabolism and Osteoporosis Research

Background:

• Statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) are investigated for potential osteoporosis treatment based on animal studies.
• Epidemiological studies suggest a link between statin use and reduced fracture risk.

Purpose of the Study:

• To investigate the association between statin treatment and the risk of hip fracture in a population-based case-control study.
• To determine if statin use influences hip fracture incidence.

Main Methods:

• A population-based case-control study involving 6,660 hip fracture cases and 33,274 matched controls in North Jutland County, Denmark.
• Data on statin prescriptions redeemed within 5 years prior to the index date were analyzed.
• Conditional logistic regression was used to estimate odds ratios (OR) for hip fracture, adjusting for confounders.

Main Results:

• Statin treatment was associated with a reduced risk of hip fracture (OR=0.68; 95% CI: 0.50-0.93) for individuals with more than three statin prescriptions.
• A dose-dependent relationship was observed, with hip fracture risk decreasing as the number of statin prescriptions increased.
• No significant differences in the association were found between genders or across different age groups.

Conclusions:

• Findings support an association between statin treatment and a reduced risk of hip fracture.
• The observed association suggests statins may have a protective effect against hip fractures.
• Further research is needed to confirm if this association is causal.